Lotus Mallbris: Influence Statistics

Lotus Mallbris

Lotus Mallbris

Eli Lilly and Company, Indianapolis, IN, USA | Division of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden | Division of ...

Lotus Mallbris: Expert Impact

Concepts for which Lotus Mallbris has direct influence: Psoriatic arthritis , Patients psoriasis , Facial psoriasis , Plaque psoriasis , Patients tofacitinib , Ixekizumab treatment , Hereditary angioedema .

Lotus Mallbris: KOL impact

Concepts related to the work of other authors for which for which Lotus Mallbris has influence: Psoriatic arthritis , Atopic dermatitis , Patients psoriasis , Metabolic syndrome , Hidradenitis suppurativa , Hereditary angioedema , Janus kinase .

KOL Resume for Lotus Mallbris

Year
2022

Eli Lilly and Company, Indianapolis, IN, USA

2021

Division of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Eli Lilly, Indianapolis, Indiana

2020

Eli Lilly and Company, Indianapolis, Indiana.

2019

Eli Lilly and Company, Indianapolis, IN, U.S.A.

Pfizer Inc, Collegeville, PA USA

2018

Inflammation and Immunology,Global Medical Affairs, Pfizer, Collegeville, PA, USA.

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, U.S.A.

2017

Unit of Dermatology and Venereology Karolinska Institutet Karolinska University Hospital Stockholm Sweden

Eli Lilly and Company, Indianapolis, Indiana, USA

Pfizer Inc, Collegeville, Pennsylvania

2016

Eli Lilly and Company, Indianapolis, Indiana

Unit of Dermatology and Venereology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Pfizer Inc. Collegeville PA U.S.A

2015

Karolinska University Hospital Unit of Dermatology and Venereology Karolinska Institutet Stockholm Sweden

Pfizer Inc Collegeville PA U.S.A

2014

Lotus Mallbris, Pfizer Global Medical Dermatology Lead, Philadelphia, USA

Pfizer Collegeville PA U.S.A

Dermatology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, and

2012

Karolinska University Hospital, Solna, Sweden

2011

Department of Medicine, Unit of Dermatology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden

2009

Unit of Dermatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

2008

Dermatology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden

2006

Department of Medicine, Dermatology Unit, Karolinska Institutet, 17176, Stockholm, Sweden

From the Units of Dermatology

2005

Dermatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

2004

Dermatology Unit, Karolinska Hospital, B2:01, SE-171 76, Stockholm, Sweden

2003

From the Units of Dermatologya and Rheumatology,b Department of Medicine, Karolinska Institute

Department of Dermatology, Karolinska Hospital, Stockholm, Sweden

2002

Dermatology and

Prominent publications by Lotus Mallbris

KOL-Index: 27722 . BACKGROUND: Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, ...
Known for 3 Trials | Ixekizumab Placebo | Week Patients | Spga Score
KOL-Index: 14588 . BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis. Psoriasis impacts on physical and psychological well-being; improvements in health-related quality of life (HRQoL) with etanercept in psoriasis are well documented. OBJECTIVE: To evaluate HRQoL with tofacitinib, vs. placebo or etanercept, in the Phase 3, randomized, placebo-controlled, ...
Known for Tofacitinib Placebo | 10 Bid | Phase 3 Study | Plaque Psoriasis
KOL-Index: 14528 . BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. OBJECTIVES: We sought to report longer-term tofacitinib efficacy and safety in patients with moderate to severe psoriasis. METHODS: Data from 2 identical phase-III studies, Oral-treatment Psoriasis Trial Pivotal 1 and 2, were pooled with data from these patients in an ongoing open-label long-term ...
Known for Patients Tofacitinib | Janus Kinase | 10 Bid | 2 Randomized
KOL-Index: 12841 . BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor being investigated for the treatment of moderate-to-severe plaque psoriasis. OBJECTIVES: To compare outcomes following tofacitinib withdrawal with outcomes of continuation. METHODS: In this phase 3 study (NCT01186744), patients received tofacitinib 5 mg (n = 331) or 10 mg (n = 335) twice daily for 24 weeks. The patients who achieved ...
Known for Tofacitinib Withdrawal | Pga Responses Patients | Chronic Plaque | Initial Treatment
KOL-Index: 12073 . IMPORTANCE: Psoriasis, psoriatic arthritis, and uveitis are inflammatory disorders with significant overlap in their inflammatory pathways. Limited evidence is available about the relationship between psoriatic disease and uveitis. OBJECTIVE: To investigate the potential bidirectional relationship between psoriatic disease, including psoriasis and psoriatic arthritis, and uveitis. DESIGN, ...
Known for Psoriatic Disease | Patients Psoriasis | Arthritis Uveitis | Nationwide Cohort
KOL-Index: 10977 . BackgroundPatients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A.ObjectiveOur aim was to assess the response to ixekizumab in patients with moderate-to-severe plaque psoriasis who did not respond adequately to etanercept using ...
Known for 12 Weeks | Ixekizumab Patients | Phase Iii | Plaque Psoriasis
KOL-Index: 10975 . BACKGROUND: Head-to-head randomized studies comparing ixekizumab and secukinumab in the treatment of psoriasis are not available. OBJECTIVES: To assess efficacy and quality of life using matching-adjusted indirect comparisons for treatment with ixekizumab vs. secukinumab. METHODS: Psoriasis Area and Severity Index (PASI) improvement of at least 75%, 90% and 100% and Dermatology Life ...
Known for Plaque Psoriasis | Indirect Comparison | Ixekizumab Secukinumab | Monoclonal Antibodies
KOL-Index: 10686 . BACKGROUND: Biologics are effective for the treatment of psoriasis. However, treatment outcomes may differ among biologic-naive patients and those switched from previous biological therapies. OBJECTIVES: The study's objective was to investigate efficacy and safety of ixekizumab, a high-affinity anti-interleukin-17A antibody, in patients with psoriasis with and without previous exposure to ...
Known for Phase Iii | Ixekizumab Patients | Integrated Analysis | Previous Exposure
KOL-Index: 10665 . BACKGROUND: The efficacy of ixekizumab, an anti-interleukin-17A (anti-IL-17A) monoclonal IgG4 antibody, was demonstrated in moderate-to-severe psoriasis patients when administered via prefilled syringe (PFS). OBJECTIVE: To evaluate the effect of two drug delivery devices on the pharmacokinetics (PK) of ixekizumab as well as efficacy and safety with both devices. METHODS: In the first ...
Known for Safety Ixekizumab | Subcutaneous Administration | 12 Weeks | Prefilled Syringe
KOL-Index: 10314 . BACKGROUND: Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) inhibitor treatment effect via topical application in patients with AD is unknown. OBJECTIVES: Tofacitinib, a small-molecule JAK inhibitor, was investigated for the topical treatment of AD. METHODS: In this 4-week, ...
Known for Topical Tofacitinib | Atopic Dermatitis | Cfb Week | Protein Kinase Inhibitors
KOL-Index: 10058 . BACKGROUND: Psoriasis, Crohn disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders with overlapping genetic architecture. However, data on the frequency and risk of CD and UC in psoriasis are scarce and poorly understood. OBJECTIVES: To investigate the association between CD and UC in patients with psoriasis. METHODS: All Danish individuals aged ≥ 18 years between 1 ...
Known for Uc Psoriasis | Inflammatory Bowel Disease | Psoriatic Arthritis | Ulcerative Colitis
KOL-Index: 10024 . BACKGROUND: Safety of biologics is important when treating patients with psoriasis. OBJECTIVE: We sought to determine the safety of ixekizumab in psoriasis. METHODS: Integrated safety data are presented from a 12-week induction period, a 12- to 60-week maintenance period, and from all ixekizumab-treated patients from 7 clinical trials. Exposure-adjusted incidence rates (IRs) per 100 ...
Known for Ixekizumab Psoriasis | Induction Period | Term Safety | Adult Antibodies Monoclonal
KOL-Index: 9904 . BACKGROUND: Infections are associated with biological therapies in psoriasis. OBJECTIVES: To summarize the incidence of infections in patients with moderate-to-severe psoriasis treated with ixekizumab, an anti-interleukin-17A monoclonal antibody. METHODS: Infections are summarized from an integrated database of seven controlled and uncontrolled ixekizumab psoriasis trials. Data are ...
Known for Ixekizumab Patients | Monoclonal Antibody | Biological Therapies | Incidence Rates
KOL-Index: 9530 . BACKGROUND: Pruritus is a clinically important symptom of psoriasis that has a major impact on quality of life (QoL). OBJECTIVE: The objective of this study was to examine pruritus and QoL in patients with moderate-to-severe psoriasis treated with etanercept (ETN) in the PRISTINE clinical trial. METHODS: Patients were randomized (1 : 1, double-blind) to ETN 50 mg QW or 50 mg BIW for 12 ...
Known for Plaque Psoriasis | Week Patients | Pruritus Quality | Life Qol
KOL-Index: 9108 . BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor. Immunomodulatory therapies can increase the risk for herpes zoster (HZ) in patients with psoriasis. OBJECTIVE: To evaluate the relationship between tofacitinib use and HZ risk. METHODS: We used phases 2 and 3 and long-term extension (LTE) data from the tofacitinib development program in psoriasis to calculate HZ incidence ...
Known for Herpes Zoster | Patients Tofacitinib | Hz Risk | Immunomodulatory Therapies

Key People For Psoriatic Arthritis

Top KOLs in the world
#1
D Gladman Gladman
psoriatic arthritis systemic lupus erythematosus patients psa
#2
Philip J Mease
psoriatic arthritis eli lilly novartis pfizer
#3
Philip S Helliwell
psoriatic arthritis tight control axial involvement
#4
Oliver M FitzGerald
psoriatic arthritis synovial tissue patients psa
#5
Christopher T Ritchlin
psoriatic arthritis radiographic progression janssen development
#6
Paul Emery
rheumatoid arthritis ankylosing spondylitis radiographic progression

Eli Lilly and Company, Indianapolis, IN, USA | Division of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden | Division of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Stockho